'World-first' vaccine designed by Artificial Intelligence

Artificial intelligence (AI) has helped create a "fundamentally new" type of vaccine. Researchers say this vaccine could protect against many viruses and prevent future pandemics.

A team at the University of Cambridge developed the vaccine. They note it's the first time a vaccine's main part was designed entirely by AI and then tested in people.

The vaccine aims to work against all coronaviruses, including all Covid variants. It also targets viruses that infect animals but could potentially cause the next pandemic.

This work is still in its early stages. However, the team is already developing other vaccines for flu and Ebola.

How the AI Vaccine Works

Vaccines teach our bodies to recognize infections, helping us fight them off. But some viruses, like those causing Covid and seasonal flu, change quickly. This means vaccines can become outdated fast, requiring regular updates.

Professor Jonathan Heeney from the University of Cambridge explained that this new approach aims to get "ahead of the curve." The goal is to protect against new outbreaks or pandemics before they even start.

Normally, vaccines are designed using a current virus strain. The Cambridge researchers, however, used genetic codes from various coronaviruses. These codes came from surveillance programs that look for potential viral threats.

An AI analyzed these genetic codes. It then designed a "super-antigen." This antigen can train the immune system to protect against an entire family of viruses. This protection works even if the viruses mutate or if a new infection jumps from animals to humans.

Antigens are key vaccine components because they are what the immune system learns to attack. Professor Heeney stated this is the first time an AI-designed antigen has been tested in people. He called the technology "surprising all of us" and "amazing what we can do with it for the good of humanity."

Heeney told BBC News that this is about creating vaccines that protect us from today's viruses and from what could cause the next outbreak. He sees it as a "fundamental shift in how we prepare for pandemics."

Early Results and Future Potential

The initial trials involved 39 people and focused on vaccine safety. A second study with about 200 people will provide more details on how well it trains the immune system.

The findings, published in the Journal of Infection, noted a "modest" impact on the immune system. Still, the results are generating excitement.

Professor Saul Faust, who helped conduct some trials at the University of Southampton, said the AI design "definitely has potential" and is "really exciting." He added that the technology is "an awful lot better at designing vaccines for potential pandemics when viruses are changing."

The Cambridge team is already researching universal seasonal flu vaccines in animals. These would not need yearly updates. They are also working on an H5N1 bird flu vaccine, in case that virus becomes a human pandemic.

Additionally, they are exploring a vaccine for viral hemorrhagic fevers, including Ebola species. The current outbreak in the Democratic Republic of Congo is caused by a species for which no vaccine yet exists.

Professor Andy Pollard, director of the Oxford Vaccine Group, was not involved in the study. However, he noted that this approach shows compelling evidence in animal research. He called it "fascinating data" and said people "wouldn't have predicted they'd be able to generate these immune responses."

Pollard believes the real test will be in human trials, as our immune systems are more complex than those of laboratory mice. More broadly, he sees AI as a "game changer" for vaccine research. AI tools could predict immune responses to vaccines, speeding up development and potentially "saving lives."

Professor Marian Knight, scientific director for the National Institute for Health and Care Research, stated that the success of this AI-designed "super-antigen" trial marks a significant step forward in achieving broad, lasting viral protection.

Deep Dive & References

Impact of a novel AI-designed pan-coronavirus vaccine in a first-in-human clinical trial - Journal of Infection, 2026